Suchergebnisse - "PRASUGREL"

Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial von Gargiulo, Giuseppe, Esposito, Giovanni, Avvedimento, Marisa, Nagler, Michael, Minuz, Pietro, Campo, Gianluca, Gragnano, Felice, Manavifar, Negar, Piccolo, Raffaele, Tebaldi, Matteo, Cirillo, Plinio, Hunziker, Lukas, Vranckx, Pascal, Leonardi, Sergio, Heg, Dik, Windecker, Stephan, Valgimigli, Marco

“… Standard administration of newer oral P2Y inhibitors, including prasugrel or ticagrelor, provides suboptimal early inhibition of platelet aggregation (IPA) in …”
Weitere Angaben

Prasugrel Intermediate Metabolite Modulates Platelet Inhibition by Negatively Interfering With an Active Metabolite: An Ex Vivo, In Vitro, and In Silico Study von Minuz, Pietro, Giorgetti, Alejandro, Meneguzzi, Alessandra, Taus, Francesco, Ribeiro, Rui P, Baldessari, Filippo, Gargiulo, Giuseppe, Gragnano, Felice, Landi, Antonio, Castelli, Marco, Gottardo, Rossella, Bortolotti, Federica, Verlato, Giuseppe, Fava, Cristiano, Cattaneo, Marco, Tagliaro, Franco, Valgimigli, Marco

“… Prasugrel is converted into prasugrel active metabolite (PAM; R-138727) through the cytochrome P450-mediated conversion of an intermediate metabolite (PIM; …”
Weitere Angaben

Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study von Motovska, Zuzana, Hlinomaz, Ota, Miklik, Roman, Hromadka, Milan, Varvarovsky, Ivo, Dusek, Jaroslav, Knot, Jiri, Jarkovsky, Jiri, Kala, Petr, Rokyta, Richard, Tousek, Frantisek, Kramarikova, Petra, Majtan, Bohumil, Simek, Stanislav, Branny, Marian, Mrozek, Jan, Cervinka, Pavel, Ostransky, Jiri, Widimsky, Petr

“… No randomized head-to-head comparison of the efficacy and safety of ticagrelor and prasugrel has been published in the 7 years since the higher efficacy of …”
Weitere Angaben

Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study von Rollini, Fabiana, Franchi, Francesco, Hu, Jenny, Kureti, Megha, Aggarwal, Niti, Durairaj, Ashwin, Park, Yongwhi, Seawell, Michael, Cox-Alomar, Pedro, Zenni, Martin M, Guzman, Luis A, Suryadevara, Siva, Antoun, Patrick, Bass, Theodore A, Angiolillo, Dominick J

“… Platelet inhibitory effects induced by oral P2Y12 receptor antagonists are delayed in patients with ST-segment elevation myocardial infarction (STEMI) …”
Weitere Angaben

Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes von Schüpke, Stefanie, Neumann, Franz-Josef, Menichelli, Maurizio, Mayer, Katharina, Bernlochner, Isabell, Wöhrle, Jochen, Richardt, Gert, Liebetrau, Christoph, Witzenbichler, Bernhard, Antoniucci, David, Akin, Ibrahim, Bott-Flügel, Lorenz, Fischer, Marcus, Landmesser, Ulf, Katus, Hugo A, Sibbing, Dirk, Seyfarth, Melchior, Janisch, Marion, Boncompagni, Duino, Hilz, Raphaela, Rottbauer, Wolfgang, Okrojek, Rainer, Möllmann, Helge, Hochholzer, Willibald, Migliorini, Angela, Cassese, Salvatore, Mollo, Pasquale, Xhepa, Erion, Kufner, Sebastian, Strehle, Axel, Leggewie, Stefan, Allali, Abdelhakim, Ndrepepa, Gjin, Schühlen, Helmut, Angiolillo, Dominick J, Hamm, Christian W, Hapfelmeier, Alexander, Tölg, Ralph, Trenk, Dietmar, Schunkert, Heribert, Laugwitz, Karl-Ludwig, Kastrati, Adnan

“… A randomized trial involving patients with acute coronary syndromes showed that prasugrel was superior to ticagrelor with regard to the incidence of death, …”
Volltext

Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial von Watanabe, Hirotoshi, Domei, Takenori, Morimoto, Takeshi, Natsuaki, Masahiro, Shiomi, Hiroki, Toyota, Toshiaki, Ohya, Masanobu, Suwa, Satoru, Takagi, Kensuke, Nanasato, Mamoru, Hata, Yoshiki, Yagi, Masahiro, Suematsu, Nobuhiro, Yokomatsu, Takafumi, Takamisawa, Itaru, Doi, Masayuki, Noda, Toshiyuki, Okayama, Hideki, Seino, Yoshitane, Tada, Tomohisa, Sakamoto, Hiroki, Hibi, Kiyoshi, Abe, Mitsuru, Kawai, Kazuya, Nakao, Koichi, Ando, Kenji, Tanabe, Kengo, Ikari, Yuji, Hanaoka, Keiichi Igarashi, Morino, Yoshihiro, Kozuma, Ken, Kadota, Kazushige, Furukawa, Yutaka, Nakagawa, Yoshihisa, Kimura, Takeshi

“… Very short mandatory dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with a drug-eluting stent may be an attractive option. To …”
Weitere Angaben

One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial von Jang, Youngwoo, Park, Sang-Don, Lee, Joon Pyo, Choi, Seong Huan, Kong, Min Gyu, Won, Yoon Sun, Kim, Minsu, Lee, Kyoung Hoon, Han, Seung Hwan, Kwon, Sung Woo, Suh, Jon, Kang, Woong Chol

“… The efficacy and safety of a 1-month prasugrel-based dual antiplatelet therapy (DAPT) strategy followed by reduced-dose prasugrel monotherapy in acute coronary …”
Weitere Angaben

Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes : Results From a Randomized Trial von Menichelli, Maurizio, Neumann, Franz-Josef, Ndrepepa, Gjin, Mayer, Katharina, Wöhrle, Jochen, Bernlochner, Isabell, Richardt, Gert, Witzenbichler, Bernhard, Sibbing, Dirk, Gewalt, Senta, Angiolillo, Dominick J, Lahu, Shqipdona, Hamm, Christian W, Hapfelmeier, Alexander, Trenk, Dietmar, Laugwitz, Karl-Ludwig, Schunkert, Heribert, Schüpke, Stefanie, Kastrati, Adnan

“… The efficacy and safety of a reduced dose of prasugrel versus a standard dose of ticagrelor in elderly patients or those with a low body weight presenting with …”
Weitere Angaben

Comparison of Heart Rates in Patients Initiated on Ticagrelor Versus Other P2Y12 Inhibitors After an Inferior ST Elevation Myocardial Infarction (STEMI) von Law, Taylor M, Wohlfarth, Kevin M

“… P2Y12 inhibitors have differing associations of bradyarrhythmias. Ticagrelor has been shown to increase adenosine plasma concentrations leading to increases in …”
Weitere Angaben

Effect of Alternative Administrations on P2Y12 Receptor Inhibitors’ Pharmacokinetics and Pharmacodynamics: Systematic Review and Meta-Analysis von Konecki, Celine, Feliu, Catherine, Scala-Bertola, Julien, Duflot, Thomas, Djerada, Zoubir

“… Alternative administrations methods, such as chewing or crushing tablets, have been proposed to improve P2Y 12 receptor inhibitors’ absorption in acute and …”
Volltext

Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome von Valgimigli, Marco, Landi, Antonio, Angiolillo, Dominick J, Baber, Usman, Bhatt, Deepak L, Bonaca, Marc P, Capodanno, Davide, Cohen, David J, Gibson, C Michael, James, Stefan, Kimura, Takeshi, Lopes, Renato D, Mehta, Shamir R, Montalescot, Gilles, Sibbing, Dirk, Steg, P Gabriel, Stone, Gregg W, Storey, Robert F, Vranckx, Pascal, Windecker, Stephan, Mehran, Roxana

“… For almost two decades, 12-month dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) has been the only class I recommendation on DAPT in American …”
Weitere Angaben

Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial von Gimbel, Marieke, Qaderdan, Khalid, Willemsen, Laura, Hermanides, Rik, Bergmeijer, Thomas, de Vrey, Evelyn, Heestermans, Ton, Tjon Joe Gin, Melvyn, Waalewijn, Reinier, Hofma, Sjoerd, den Hartog, Frank, Jukema, Wouter, von Birgelen, Clemens, Voskuil, Michiel, Kelder, Johannes, Deneer, Vera, ten Berg, Jurriën

“… Current guidelines recommend potent platelet inhibition with ticagrelor or prasugrel in patients after an acute coronary syndrome. However, data about optimal …”
Volltext

Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials von Galli, Mattia, Benenati, Stefano, Franchi, Francesco, Rollini, Fabiana, Capodanno, Davide, Biondi-Zoccai, Giuseppe, Vescovo, Giovanni Maria, Cavallari, Larisa H, Bikdeli, Behnood, Ten Berg, Jurrien, Mehran, Roxana, Gibson, Charles Michael, Crea, Filippo, Pereira, Naveen L, Sibbing, Dirk, Angiolillo, Dominick J

“… Guidelines recommend the use of potent P2Y12 inhibitors over clopidogrel for the reduction of ischaemic events in patients with acute coronary syndrome (ACS) …”
Weitere Angaben

Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction von Thomas, Mark R, Morton, Allison C, Hossain, Rashed, Chen, Beining, Luo, Lei, Shahari, Nur Nazihah B Md, Hua, Peng, Beniston, Richard G, Judge, Heather M, Storey, Robert F

“… Delays in the onset of action of prasugrel during primary percutaneous coronary intervention (PPCI) have been reported and could be related to the effects of …”
Weitere Angaben

Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers von Hobl, Eva-Luise, Reiter, Birgit, Schoergenhofer, Christian, Schwameis, Michael, Derhaschnig, Ulla, Lang, Irene Marthe, Stimpfl, Thomas, Jilma, Bernd

“… Background Morphine decreases the concentrations and effects of clopidogrel, which could lead to treatment failure in myocardial infarction. Objectives To …”
Volltext

Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study von Navarese, Eliano P., Kolodziejczak, Michalina, Winter, Max-Paul, Alimohammadi, Arman, Lang, Irene M., Buffon, Antonino, Lip, Gregory YH, Siller-Matula, Jolanta M.

“… Circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme might be associated with increased activation of platelets. We aimed to assess the …”
Volltext

Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study von Cuisset, Thomas, Deharo, Pierre, Quilici, Jacques, Johnson, Thomas W, Deffarges, Stéphanie, Bassez, Clémence, Bonnet, Guillaume, Fourcade, Laurent, Mouret, Jean Philippe, Lambert, Marc, Verdier, Valentine, Morange, Pierre Emmanuel, Alessi, Marie Christine, Bonnet, Jean Louis

“… Newer P2Y12 blockers (prasugrel and ticagrelor) demonstrated significant ischaemic benefit over clopidogrel after acute coronary syndrome (ACS). However, both …”
Weitere Angaben

Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial von Sibbing, Dirk, Aradi, Dániel, Gross, Lisa, Trenk, Dietmar, Geisler, Tobias, Orban, Martin, Hadamitzky, Martin, Merkely, Béla, Kiss, Róbert Gábor, Komócsi, András, Dézsi, Csaba A, Holdt, Lesca, Felix, Stephan B, Parma, Radoslaw, Schwinger, Robert H G, Rieber, Johannes, Huber, Kurt, Neumann, Franz-Josef, Koltowski, Lukasz, Mehilli, Julinda, Massberg, Steffen, Parma, Radoslaw, Parma, Zofia, Lesiak, Maciej, Komosa, Anna, Huczek, Zenon, Koltowski, Lukasz, Kowara, Michal, Rymuza, Bartosz, Klopotowski, Mariusz, Veress, Gábor, Dézsi, András Döme, Merkely, Béla, Lux, Árpád, Kiss, Róbert Gábor, Papp, Judit, Kovács, Andrea, Dézsi, Csaba András, Amer, Sayour, Róna, Szilárd, Komócsi, András, Ili, Renáta, Ungi, Imre, Zweiker, Robert, Tóth-Gayor, Gábor, Huber, Kurt, Haller, Paul, von Scheidt, Wolfgang, Blüthgen, Andreas, Neumann, Franz-Josef, Trenk, Dietmar, Leggewie, Stefan, Kreider-Stempfle, Hans Ulrich, Kara, Kaffer, Mügge, Andreas, Fichtlscherer, Stephan, Zeiher, Andreas M., Seeger, Florian, Hinterseer, Martin, König, Andreas, Lederle, Susanne, Jacobshagen, Claudius, Czepluch, Frauke, Maier, Lars, Schillinger, Wolfgang, Sossalla, Samuel, Hummel, Astrid, Felix, Stephan, Karakas, Mahir, Sydow, Karsten, Rudolph, Tanja, Halbach, Marcel, Gori, Tommaso, Münzel, Thomas, May, Andreas, Gerstenberg, Carsten-Manuel, Pilecky, David, Rieber, Johannes, Deichstetter, Markus, Sibbing, Dirk, Gross, Lisa, Kääb, Stefan, Löw, Anja, Orban, Martin, Sattler, Stefan, Teupser, Daniel, Holdt, Lesca, Räder, Thomas, Schütz, Torsten, Vahldiek, Felix, Divchev, Dimitar, Ince, Hüseyin, Nienaber, Christoph A, Radunski, Henning, Boekstegers, Peter, Horstkotte, Jan, Mueller, Ralf, Geisler, Tobias, Schwinger, Robert, Rasp, Oliver

“… Current guidelines recommend potent platelet inhibition with prasugrel or ticagrelor for 12 months after an acute coronary syndrome managed with percutaneous …”
Volltext

Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study von Franchi, Francesco, Rollini, Fabiana, Aggarwal, Niti, Hu, Jenny, Kureti, Megha, Durairaj, Ashwin, Duarte, Valeria E, Cho, Jung Rae, Been, Latonya, Zenni, Martin M, Bass, Theodore A, Angiolillo, Dominick J

“… Patients with diabetes mellitus (DM) are at increased risk of atherothrombotic events, underscoring the importance of effective platelet inhibiting therapies …”
Weitere Angaben

Ticagrelor versus Adjusted‐Dose Prasugrel in Acute Coronary Syndrome with Percutaneous Coronary Intervention von Tsai, Ming‐Lung, Lin, Yuan, Chen, Dong‐Yi, Lin, Ming‐Shyan, Wang, Chao‐Yung, Hsieh, I‐Chang, Yang, Ning‐I, Hung, Ming‐Jui, Chen, Tien‐Hsing

“… Dual antiplatelet therapy (DAPT) with ticagrelor or adjusted‐dose prasugrel has been used for acute coronary syndrome (ACS). However, few studies have directly …”
Volltext